Memphasys Secures European Felix Agreement
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Memphasys Ltd has announced a new exclusive distribution agreement for its Felix™ System in Europe, specifically covering the Czech Republic, Slovakia, and Kazakhstan. The agreement includes a minimum purchase commitment over three years, which is expected to increase as adoption of the Felix™ System grows. This partnership with INVIDO LAB aims to enhance Memphasys' commercial presence in established IVF markets and drive recurring revenue through single-use cartridges. The company has also strengthened its European operations by appointing a new director to lead commercial activities in the region.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Memphasys
- Felix Registration Achieved in Turkey, Sales Commence
- EUR526,500 Nordic Agreement Expands Felix European Footprint
- Felix Early Thai FDA Approval, Commercial Launch Accelerates
- Felix Registration Achieved in Vietnam and Cartridge Order
- European Commercial Roll-out continues with Poland Agreement
Later from Memphasys
- Potential Expedited FDA Pathway to US IVF Market
- Memphasys receives A$3.5 million from Peters Investments
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys